RFK Jr. Appoints Peptide Advocates to FDA Advisory Panel

U.S. Health Secretary Robert F. Kennedy Jr. has appointed nine new members to the FDA's Pharmacy Compounding Advisory Committee (PCAC), a move that has drawn criticism due to the appointees' financial ties to peptide promotion. The appointments increase the panel's membership to thirteen, with a focus on potentially reversing restrictions on a dozen injectable peptides that FDA scientists have deemed unproven and potentially harmful.
The PCAC is scheduled to meet on July 23-24, 2026, to discuss seven peptides, including BPC-157 and TB-500, with a follow-up meeting planned before February 2027 to review additional peptides. The central issue is whether compounding pharmacies should be allowed to produce these peptides for human use, rather than being restricted to 'research use only.'
FDA career scientists have publicly opposed easing restrictions, citing insufficient evidence of safety and efficacy for the peptides under review. Recent FDA enforcement actions against compounding facilities for contamination and quality control violations underscore the regulatory concerns.
Critics, including FDA staff, emphasize the lack of robust evidence supporting the peptides' use in humans, while many of the newly appointed panelists are practitioners who prescribe or promote these substances, often without FDA approval.